- Home
- KIDS vs COGT Comparison
KIDS vs COGT Comparison
Compare KIDS & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIDS
- COGT
- Stock Information
- Founded
- KIDS 2007
- COGT 2014
- Country
- KIDS United States
- COGT United States
- Employees
- KIDS N/A
- COGT N/A
- Industry
- KIDS Medical/Dental Instruments
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- KIDS Health Care
- COGT Health Care
- Exchange
- KIDS Nasdaq
- COGT Nasdaq
- Market Cap
- KIDS 601.5M
- COGT 545.3M
- IPO Year
- KIDS 2017
- COGT 2018
- Fundamental
- Price
- KIDS $22.04
- COGT $4.81
- Analyst Decision
- KIDS Buy
- COGT Buy
- Analyst Count
- KIDS 7
- COGT 7
- Target Price
- KIDS $35.71
- COGT $14.00
- AVG Volume (30 Days)
- KIDS 133.8K
- COGT 1.3M
- Earning Date
- KIDS 05-07-2025
- COGT 05-06-2025
- Dividend Yield
- KIDS N/A
- COGT N/A
- EPS Growth
- KIDS N/A
- COGT N/A
- EPS
- KIDS N/A
- COGT N/A
- Revenue
- KIDS $212,453,000.00
- COGT N/A
- Revenue This Year
- KIDS $18.99
- COGT N/A
- Revenue Next Year
- KIDS $17.04
- COGT N/A
- P/E Ratio
- KIDS N/A
- COGT N/A
- Revenue Growth
- KIDS 31.28
- COGT N/A
- 52 Week Low
- KIDS $20.25
- COGT $3.72
- 52 Week High
- KIDS $35.99
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- KIDS 49.93
- COGT 44.64
- Support Level
- KIDS $20.69
- COGT $4.55
- Resistance Level
- KIDS $23.63
- COGT $5.89
- Average True Range (ATR)
- KIDS 1.13
- COGT 0.38
- MACD
- KIDS 0.27
- COGT 0.09
- Stochastic Oscillator
- KIDS 53.00
- COGT 34.55
About KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.